Solid Dosage
GEA designs, produces and delivers innovative, integrated solutions for every stage of the manufacturing process of anti-diabetic drugs
With diabetes and the global anti-diabetes drug market on the rise, demand for GEA technologies for the production of these life-saving drugs is already high and set to increase, particularly in new markets and emerging economies
It is estimated that approximately 6.4% of the adult population worldwide has diabetes, leading to a huge demand for oral anti-diabetes drugs. To be able to cater for this demand, high-volume or mass production of these medicines is a fundamental requirement. It enables companies to produce goods faster and reduce the overall per unit production cost, allowing them to make anti-diabetes medications available to less-developed countries.
GEA has been instrumental in designing, producing and delivering innovative, integrated solutions for every stage of the manufacturing process: from materials handling to tablet coating, automation and monitoring. We continue to support this high-volume batch-based production with ongoing improvements and innovative developments.
One example is our range of double-sided tablet presses to accommodate the fact that many oral anti-diabetes medicines are bilayer combination drugs, consisting of two separate layers for each API.
Another trend that we have observed is the move towards continuous manufacturing (CM). Providing increased yields, lower utility consumption and reduced waste, CM meets the industry’s demands for improved production economics and increased manufacturing flexibility.
Focusing on quality during the whole product lifecycle and decreasing any associated risks, GEA is helping its customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
Weergegeven 4 van 25
Door procesbewaking met behulp van online analysesystemen te combineren met vaste principes van procesengineering en geavanceerde procesmodelleringstechnieken, kunnen processen actief bestuurd worden om invoervariaties te compenseren.
Innovatieve CIP-concepten van GEA voldoen aan hoge normeringen. Onze experts garanderen productveiligheid in elke fase van het proces. Elke upgrade wordt aangepast aan individuele plaatselijke situaties en eisen van de klant, en leidt tot aanzienlijke besparingen.
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Afvalreductie is belangrijk voor ons bij GEA en door de kracht van vriesdroogtechnologie te benutten, kunnen we voedseloverschotten omzetten in waardevolle, duurzame producten die ons helpen afval te reduceren, de houdbaarheid te verlengen en een beter bestendige voedselvoorzieningsketen voor toekomstige generaties te creëren.
Toen de Zuid-Koreaanse ‘plant-forward’ voedselproducent Pulmuone bij GEA aanklopte met de uitdaging om een moderne draai aan de traditionele taaie koude (naengmyeon-) noodle te geven, konden de R&D-experts van GEA de uitdaging aan. Ze hielpen met de ontwikkeling van wat nu een commerciële hit is die met minder water en elektriciteit wordt geproduceerd dan de reeds bestaande methoden. Het resultaat is ook getrouw aan de traditionele oorsprong van het gerecht, evenals de wortels van Pulmuone op het gebied van gezondheid, welzijn en duurzaamheid.